Epitalon

Updated May 19, 2026. This pillar guide has been expanded from its original stub with research context, regulatory status, clinical evidence assessment, and prescriber guidance. The PeptidesBeat full compound profile provides a comprehensive overview for patients and practitioners navigating the post-April 15 regulatory landscape.

Quick Summary

• Epitalon (also known as Epithalamin or AEDG peptide) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal gland peptide epithalamin.
• Primarily studied in preclinical and small human trials for pineal gland function, melatonin regulation, and circadian rhythm support.
• Russian research from the 1990s–2000s is the dominant source of published data; Western clinical trials are limited.
• Reclassified by the FDA to Category 2 (significant safety concerns) on April 15, 2026.
• July 23–24, 2026 PCAC meeting will determine its final 503A Bulks List status.
• Not FDA-approved for any indication. Available through compounding pharmacies under valid prescriptions.

What Is Epitalon?

Epitalon is a synthetic tetrapeptide with the amino acid sequence Ala-Glu-Asp-Gly (AEDG). It was developed by Russian scientists at the St. Petersburg Institute of Bioregulation and Gerontology, where it was studied as a synthetic analog of epithalamin — a polypeptide complex extracted from the bovine pineal gland.

The peptide was designed to mimic the regulatory functions of the pineal gland, particularly its role in melatonin production and circadian rhythm maintenance. Unlike many other peptides in the FDA’s April 2026 reclassification — such as BPC-157 and TB-500 — Epitalon has a distinct mechanistic profile focused on neuroendocrine regulation rather than tissue repair or metabolic function.

The tetrapeptide structure (four amino acids) means Epitalon is a relatively small molecule. This small size influences its stability profile, route of administration, and pharmacokinetics — factors that differ significantly from larger peptide hormones like GLP-1 agonists.

The Research Landscape

Published Studies

The available research on Epitalon is dominated by a single research group — the St. Petersburg Institute of Bioregulation and Gerontology — and spans primarily Russian-language journals from the 1990s through the 2000s. Key findings from this body of work include:

• Pineal gland activation: Animal studies suggest Epitalon stimulates pinealocyte function and melatonin synthesis. Rodent studies report increased nocturnal melatonin peak after Epitalon administration.
• Telomere length: One of the most cited lines of research involves Epitalon’s reported effect on telomerase activity. A 2003 study by Khavinson et al. reported that Epitalon increased telomere length in cultured human cells, a finding that has been referenced extensively in longevity-focused peptide marketing.
• Circadian rhythm: Small human trials (primarily in elderly subjects) report improvements in sleep quality, circadian rhythm normalization, and subjective well-being.
• Immune function: Preclinical studies suggest modulation of T-cell activity and antioxidant enzyme expression.

Critical Assessment

The evidence base for Epitalon has important limitations that patients and prescribers should understand:

1. Small sample sizes. The human studies that exist typically involve 20–50 subjects, far below the population size expected for clinical trial registration.
2. Lack of replication. Few independent research groups have attempted to replicate the St. Petersburg group’s findings. The telomere-length results in particular have not been confirmed in a Western laboratory setting.
3. Language and access barriers. Much of the primary research was published in Russian and is not indexed in PubMed or other standard biomedical databases, making independent verification difficult.
4. No FDA-reviewed data. None of the available Epitalon studies meet the evidentiary standard required for FDA drug approval. The peptide has never been the subject of an Investigational New Drug (IND) application.

Regulatory Status

Pre-April 2026

Before April 15, 2026, Epitalon existed in a regulatory gray zone typical of many peptides circulating in the U.S. wellness market. It was neither an FDA-approved drug nor an explicitly prohibited substance. Compounding pharmacies could legally prepare Epitalon under valid prescriptions using the 503A compounding pathway, though its status on the FDA’s Bulk Substances List was ambiguous.

April 15 Reclassification

On April 15, 2026, the FDA reclassified Epitalon along with 11 other peptides to Category 2 (substances that raise significant safety concerns when used as bulk drug substances for compounding). This reclassification means the FDA has identified potential risks associated with Epitalon compounding — primarily the absence of adequate safety data — while leaving the final regulatory determination to the Pharmacy Compounding Advisory Committee (PCAC).

July PCAC Timeline

The PCAC meeting scheduled for July 23–24, 2026 will evaluate Epitalon and six other Category 2 peptides. The committee will consider:

• Whether there is sufficient evidence of medical need for Epitalon as a compounded product.
• Whether the safety concerns identified in the Category 2 designation can be adequately managed through the compounding regulatory framework.
• Whether Epitalon should be added to the 503A Bulks List (which would permit continued compounding) or remain restricted.

Important distinction: Unlike GHK-Cu (which was placed in Category 1 — enforcement discretion), Epitalon faces the more stringent Category 2 classification. Its PCAC review is scheduled for July 2026, not early 2027.

Administration and Safety

Dosing and Route

Epitalon is typically administered via subcutaneous injection, usually in cycles of 5–10 mg per day for 10–20 days. Some protocols use intranasal administration. These dosing patterns are drawn from the published Russian studies and practitioner experience — not from FDA-reviewed clinical trials.

Important: The above administration information is presented for reference only. Dosing recommendations should always come from a licensed prescriber. There is no FDA-approved Epitalon dosing protocol.

Safety Signals

The available literature reports Epitalon as generally well-tolerated in the studied populations (primarily elderly subjects in short-term protocols). Reported side effects are mild and include injection site reactions, transient sleep pattern changes, and mild headache. No serious adverse events have been reported in the published studies, but the total number of subjects studied remains too small to draw robust safety conclusions.

The FDA’s Category 2 designation signals that the agency considers the safety data insufficient rather than evidence of harm. This is a critical distinction: Category 2 does not mean “proven dangerous” — it means “not enough evidence to determine safety.”

Clinical Evidence Gap

Epitalon exemplifies the central challenge of the peptide regulatory debate. The compound has a decades-long history of preclinical and small-scale human research, particularly in the Russian gerontology tradition, but almost none of that research meets the evidentiary standards required for FDA approval or modern evidence-based medicine.

Patients considering Epitalon should understand:

• The mechanistic rationale (pineal gland activation, circadian rhythm support) has biological plausibility but limited confirmatory data.
• The most frequently cited claims — telomere elongation, lifespan extension — rest on a narrow base of non-replicated studies.
• The absence of serious adverse events in small studies does not constitute proof of long-term safety.
• Every compounded Epitalon prescription carries the inherent risks of any non-FDA-approved injectable: sterility concerns, dosing variability, and lack of standardized quality control.

Sourcing Framework

Because Epitalon is not FDA-approved, patients who obtain it through compounding must take extra precautions:

1. Licensed prescriber only. Work with a physician who can evaluate whether Epitalon is appropriate for your specific health status and goals. Avoid telehealth services that offer peptides without a comprehensive medical evaluation.
2. PCAB-accredited pharmacy. Source only from compounding pharmacies accredited by the Pharmacy Compounding Accreditation Board (PCAB). Accreditation ensures sterility, potency, and quality control standards are met.
3. State law compliance. Some states have additional restrictions on peptide prescribing and dispensing. Verify your state’s rules using the state-by-state tracker.
4. See the Peptide Law Playbook. The 2026 Peptide Law Playbook provides a comprehensive framework for navigating prescriber conversations, pharmacy verification, and legal compliance.

Key Takeaways

Topic	Status
FDA-approved indications	None
FDA Category (since April 15, 2026)	Category 2 (significant safety concerns)
PCAC review	July 23–24, 2026
Primary research base	Russian preclinical and small human studies, 1990s–2000s
Replication status	Limited independent replication
Compounding availability	Available under valid prescription through 503A pharmacies
U.S. legal pathway	PCAC decision in July 2026 will determine long-term access

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.